Ypsilon Therapeutics
Ypsilon Therapeutics is developing next-generation T-cell receptor mimic (TCRm) antibodies to treat difficult-to-treat solid tumors. Their lead program focuses on highly specific targeting of cancer cells using bispecific T cell engager molecules. This approach offers a novel method for precise and effective cancer treatment.
Funding Round: Seed
Funding Amount: $2.7M
Date: 30-Jan-2025
Investors: Cancer Prevention & Research Institute of Texas (CPRIT), 82VS, Alloy Therapeutics
Markets: Biotechnology, Oncology, Immunotherapy, Health Care, Medical, Therapeutics
HQ: Waltham, Massachusetts, United States
Founded:
Website: https://ypsilontx.com/
LinkedIn: https://www.linkedin.com/company/ypsilontx
Crunchbase: https://www.crunchbase.com/organization/ypsilon-therapeutics
Leave a Comment
Comments
No comments yet.